发明名称 14'alpha',17'alpha'-C2-BRIDGED 19-NOR-PROGESTERONE DERIVATIVES.
摘要 <p>The invention concerns 14,17-C2-bridged steroids of general formula (I), wherein: R3 represents an oxygen atom, the hydroxy amino group or two hydrogen atoms; R6 represents either a hydrogen, fluorine, chlorine or bromine atom or a C1-C4 alkyl group at the 'alpha' or 'beta' position, R6' and R7 then representing hydrogen atoms; or alternatively, R6 represents a hydrogen, fluorine, chlorine or bromine atom or a C1-C4 alkyl group, R6' and R7 then representing a common additional bond; R7 represents a C1-C4 alkyl group at the 'alpha' or 'beta' position, R6 and R6' then representing hydrogen atoms; or alternatively R6 and R7 together represent a methylene group at the 'alpha' or 'beta' position and R6' represents a hydrogen atom; or R6 and R6' together represent an ethylene or methylene group and R7 represents a hydrogen atom; R9 and R10 each represent a hydrogen atom or a common bond; R11 and R12 each represent a hydrogen atom or a common bond; R13 represents a methyl or ethyl group; R15 represents a hydrogen atom or a C1-C3 alkyl group; R16 and R16' independently of one another represent a hydrogen atom, a C1-C3 alkyl group, or a C2-C4 alkenyl group, or together represent a C1-C3 alkylidene group; R15 and R16 represent a common bond and R16' represents a hydrogen atom or a C1-C3 alkyl group, or alternatively R15 and R16 together represent a ring of the partial formula (i) shown, in which n = 1 and 2 and X represents a methylene group or an oxygen atom; and R16' represents a hydrogen atom; R171 represents a hydrogen atom or a C1-C3 alkyl group; R172 represents a hydrogen atom, a C1-C3 alkyl group or a C2-C4 alkenyl group; R171' and R172' each represent a hydrogen atom or a common bond; R21 represents a hydrogen atom or a C1-C3 alkyl group; and R21' represents a hydrogen atom, C1-C3 alkyl group or hydroxy group. The claimed compounds do not include 14,17-ethano-19-norpregn-4-en-3,20-dione. The novel compounds, unlike the one disclaimed, show a high level of gestagenic activity even after peroral administration and are suitable for use in the production of medicaments.</p>
申请公布号 MX9704774(A) 申请公布日期 1997.10.31
申请号 MX19970004774 申请日期 1995.12.23
申请人 SCHERING AKTIENGESELLSCHAFT 发明人 KLAUS SCHOELLKOPF;WOLFGANG HALFBRODT;JOACHIM KUHNKE;WOLFGANG SCHWEDE;KARL-HEINRICH FRITZEMEIER;ROLF KRATTENMACHER;HANS-PETER MUHN
分类号 A61K31/56;A61K31/58;A61P43/00;C07J53/00;C07J71/00;(IPC1-7):C07J53/00 主分类号 A61K31/56
代理机构 代理人
主权项
地址